Tufton Capital Management Bristol Myers Squibb CO Transaction History

Tufton Capital Management

$532 Million
Q3 2024

A detailed history of Tufton Capital Management transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Tufton Capital Management holds 82,699 shares of BMY stock, worth $4.82 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares

82,699

Previous 87,331 5.3%

Holding current value

$4.82 Million

Previous $3.63 Million 18.01%

% of portfolio

0.8%

Previous 0.71%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$39.66 - $51.75 $183,705 - $239,706	-4,632 Reduced 5.3%	82,699 $4.28 Million
Q2 2024 Jul 31, 2024	SELL	$40.25 - $52.99 $189,537 - $249,529	-4,709 Reduced 5.12%	87,331 $3.63 Million
Q1 2024 May 07, 2024	SELL	$47.98 - $54.4 $2.04 Million - $2.31 Million	-42,508 Reduced 31.59%	92,040 $4.99 Million
Q4 2023 Jan 31, 2024	SELL	$48.48 - $57.85 $280,602 - $334,835	-5,788 Reduced 4.12%	134,548 $6.9 Million
Q3 2023 Oct 30, 2023	SELL	$57.89 - $64.73 $145,767 - $162,990	-2,518 Reduced 1.76%	140,336 $8.15 Million
Q2 2023 Jul 28, 2023	SELL	$63.71 - $70.74 $162,333 - $180,245	-2,548 Reduced 1.75%	142,854 $9.14 Million
Q1 2023 Apr 19, 2023	SELL	$65.71 - $74.53 $59,598 - $67,598	-907 Reduced 0.62%	145,402 $10.1 Million
Q4 2022 Jan 26, 2023	SELL	$68.48 - $81.09 $192,291 - $227,700	-2,808 Reduced 1.88%	146,309 $0
Q3 2022 Oct 21, 2022	SELL	$0.13 - $76.84 $4,258 - $2.52 Million	-32,760 Reduced 18.01%	149,117 $10.6 Million
Q2 2022 Jul 20, 2022	SELL	$72.62 - $79.98 $42,410 - $46,708	-584 Reduced 0.32%	181,877 $14 Million
Q1 2022 Apr 25, 2022	SELL	$61.48 - $73.72 $166,180 - $199,265	-2,703 Reduced 1.46%	182,461 $13.3 Million
Q4 2021 Jan 28, 2022	BUY	$53.63 - $62.52 $50,144 - $58,456	935 Added 0.51%	185,164 $11.5 Million
Q3 2021 Oct 21, 2021	SELL	$59.17 - $69.31 $6,390 - $7,485	-108 Reduced 0.06%	184,229 $10.9 Million
Q2 2021 Jul 29, 2021	SELL	$61.91 - $67.42 $376,660 - $410,183	-6,084 Reduced 3.2%	184,337 $12.3 Million
Q1 2021 Apr 22, 2021	BUY	$59.34 - $66.74 $93,104 - $104,715	1,569 Added 0.83%	190,421 $12 Million
Q4 2020 Feb 01, 2021	BUY	$57.74 - $65.43 $308,504 - $349,592	5,343 Added 2.91%	188,852 $11.7 Million
Q3 2020 Oct 23, 2020	SELL	$57.43 - $63.64 $80,402 - $89,096	-1,400 Reduced 0.76%	183,509 $11.1 Million
Q2 2020 Jul 27, 2020	SELL	$54.82 - $64.09 $1,644 - $1,922	-30 Reduced 0.02%	184,909 $10.9 Million
Q1 2020 Apr 23, 2020	SELL	$46.4 - $67.43 $24,731 - $35,940	-533 Reduced 0.29%	184,939 $10.3 Million
Q4 2019 Jan 24, 2020	BUY	$49.21 - $64.19 $716,202 - $934,221	14,554 Added 8.52%	185,472 $11.9 Million
Q3 2019 Oct 25, 2019	SELL	$42.77 - $50.71 $70,570 - $83,671	-1,650 Reduced 0.96%	170,918 $8.67 Million
Q2 2019 Jul 26, 2019	BUY	$44.62 - $49.34 $243,045 - $268,754	5,447 Added 3.26%	172,568 $7.83 Million
Q1 2019 Apr 29, 2019	BUY	$45.12 - $53.8 $194,783 - $232,254	4,317 Added 2.65%	167,121 $7.97 Million
Q4 2018 Jan 28, 2019	SELL	$48.76 - $63.23 $122,826 - $159,276	-2,519 Reduced 1.52%	162,804 $8.46 Million
Q3 2018 Oct 26, 2018	SELL	$55.19 - $62.25 $104,309 - $117,652	-1,890 Reduced 1.13%	165,323 $10.3 Million
Q2 2018 Aug 06, 2018	SELL	$50.53 - $62.98 $61,090 - $76,142	-1,209 Reduced 0.72%	167,213 $9.25 Million
Q1 2018 Apr 23, 2018	SELL	$59.92 - $68.98 $204,027 - $234,876	-3,405 Reduced 1.98%	168,422 $10.7 Million
Q4 2017 Jan 26, 2018	SELL	$59.94 - $65.35 $16,903 - $18,428	-282 Reduced 0.16%	171,827 $10.5 Million
Q3 2017 Oct 20, 2017	BUY	$55.23 - $63.74 $9.51 Million - $11 Million	172,109	172,109 $11 Million

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tufton Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Tufton Capital Management with notifications on news.

Account

Tufton Capital Management Bristol Myers Squibb CO Transaction History